{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:50:20Z","timestamp":1783813820547,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,26]],"date-time":"2015-05-26T00:00:00Z","timestamp":1432598400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1432-5","type":"journal-article","created":{"date-parts":[[2015,5,25]],"date-time":"2015-05-25T18:20:46Z","timestamp":1432578046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients &gt;60\u00a0years with acute myeloid leukemia who are ineligible for induction chemotherapy"],"prefix":"10.1186","volume":"15","author":[{"given":"Olga","family":"Grishina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schmoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Hackanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Lubrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette M.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Cieslik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,26]]},"reference":[{"key":"1432_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/5047","volume":"21","author":"EE Cameron","year":"1999","unstructured":"Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103\u20137.","journal-title":"Nat Genet"},{"key":"1432_CR2","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1182\/blood-2003-07-2431","volume":"103","author":"M Milhem","year":"2004","unstructured":"Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajah Y, et al. Modification of hematopoietic stem cell fate by 5aza 2\u2032deoxycytidine and trichostatin A. Blood. 2004;103:4102\u201310.","journal-title":"Blood"},{"key":"1432_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.exphem.2005.10.002","volume":"34","author":"H Araki","year":"2006","unstructured":"Araki H, Mahmud N, Milhem M, Nunez R, Xu M, Beam CA, et al. Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Exp Hematol. 2006;34:140\u20139.","journal-title":"Exp Hematol"},{"key":"1432_CR4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1158\/0008-5472.CAN-04-3011","volume":"65","author":"G Bug","year":"2005","unstructured":"Bug G, G\u00fcl H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, et al. Valproic Acid Stimulates Proliferation and Self-renewal of Hematopoietic Stem Cells. Cancer Res. 2005;65:2537\u201341.","journal-title":"Cancer Res"},{"key":"1432_CR5","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","volume":"108","author":"G Garcia-Manero","year":"2006","unstructured":"Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271\u20139.","journal-title":"Blood"},{"key":"1432_CR6","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","volume":"25","author":"W Blum","year":"2007","unstructured":"Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25:3884\u201391.","journal-title":"J Clin Oncol"},{"key":"1432_CR7","doi-asserted-by":"crossref","unstructured":"Issa J-P, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 2015, 121:556\u2013561.","DOI":"10.1002\/cncr.29085"},{"key":"1432_CR8","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/sj.leu.2403528","volume":"18","author":"RF Schlenk","year":"2004","unstructured":"Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61\u00a0years or older with acute myeloid leukemia. Leukemia. 2004;18:1798\u2013803.","journal-title":"Leukemia"},{"key":"1432_CR9","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","volume":"93","author":"EH Estey","year":"1999","unstructured":"Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, et al. Randomized phase II study of fludarabine\u2009+\u2009cytosine arabinoside\u2009+\u2009idarubicin +\/\u2212 all-trans retinoic acid +\/\u2212 granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999;93:2478\u201384.","journal-title":"Blood"},{"key":"1432_CR10","first-page":"1794","volume":"104","author":"AK Burnett","year":"2004","unstructured":"Burnett AK, Milligan D, Hills RK, Goldstone AH, Prentice AG, Wheatley K, et al. Does All-Transretinoic Acid (ATRA) Have a Role in Non-APL Acute Myeloid Leukaemia?: Results from 1666 Patients in Three MRC Trials. ASH Annu Meet Abstr. 2004;104:1794.","journal-title":"ASH Annu Meet Abstr"},{"key":"1432_CR11","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1182\/blood-2005-10-4202","volume":"107","author":"DW Milligan","year":"2006","unstructured":"Milligan DW, Wheatley K, Littlewood T, Craig JIO, Burnett AK, NCRI Haematological Oncology Clinical Studies Group. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 2006;107:4614\u201322.","journal-title":"Blood"},{"key":"1432_CR12","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1038\/sj.leu.2403530","volume":"18","author":"E Estey","year":"2004","unstructured":"Estey E. Clinical trials in AML of the elderly: should we change our methodology? Leukemia. 2004;18:1772\u20134.","journal-title":"Leukemia"},{"key":"1432_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3324\/haematol.2011.048231","volume":"97","author":"M L\u00fcbbert","year":"2012","unstructured":"L\u00fcbbert M, R\u00fcter BH, Claus R, Schmoor C, Schmid M, Germing U, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97:393\u2013401.","journal-title":"Haematologica"},{"key":"1432_CR14","doi-asserted-by":"publisher","first-page":"e75258","DOI":"10.1371\/journal.pone.0075258","volume":"8","author":"N Blagitko-Dorfs","year":"2013","unstructured":"Blagitko-Dorfs N, Jiang Y, Duque-Afonso J, Hiller J, Yalcin A, Greve G, et al. Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat. PLoS One. 2013;8:e75258.","journal-title":"PLoS One"},{"key":"1432_CR15","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/sj.leu.2403773","volume":"19","author":"MR Trus","year":"2005","unstructured":"Trus MR, Yang L, Suarez SF, Bordeleau L, Jurisica I, Minden MD. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia. 2005;19:1161\u20138.","journal-title":"Leukemia"},{"key":"1432_CR16","doi-asserted-by":"publisher","first-page":"8903","DOI":"10.1158\/0008-5472.CAN-05-2726","volume":"66","author":"G Cimino","year":"2006","unstructured":"Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, et al. Sequential valproic acid\/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res. 2006;66:8903\u201311.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"1432_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00277-005-0026-8","volume":"84","author":"A Kuendgen","year":"2005","unstructured":"Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol. 2005;84 Suppl 1:61\u20136.","journal-title":"Ann Hematol"},{"key":"1432_CR18","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1002\/cncr.21589","volume":"104","author":"G Bug","year":"2005","unstructured":"Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer. 2005;104:2717\u201325.","journal-title":"Cancer"},{"key":"1432_CR19","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","volume":"110","author":"AO Soriano","year":"2007","unstructured":"Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302\u20138.","journal-title":"Blood"},{"key":"1432_CR20","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642\u20139.","journal-title":"J Clin Oncol"},{"key":"1432_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H Dohner","year":"2010","unstructured":"Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453\u201374.","journal-title":"Blood"},{"key":"1432_CR22","first-page":"300","volume":"110","author":"M Lubbert","year":"2007","unstructured":"Lubbert M, Ruter B, Claus R, Schmid M, Germing U, Eimermacher H, et al. Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study. ASH Annu Meet Abstr. 2007;110:300.","journal-title":"ASH Annu Meet Abstr"},{"key":"1432_CR23","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1136\/bmj.311.7013.1145","volume":"311","author":"MJ Campbell","year":"1995","unstructured":"Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ. 1995;311:1145\u20138.","journal-title":"BMJ"},{"key":"1432_CR24","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO;2-S","volume":"17","author":"FY Hsieh","year":"1998","unstructured":"Hsieh FY, Bloch DA, Larsen MD. A simple method of sample size calculation for linear and logistic regression. Stat Med. 1998;17:1623\u201334.","journal-title":"Stat Med"},{"key":"1432_CR25","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Gr\u00f8nvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. European Organisation for Research and Treatment of Cancer Brussels; 2001."},{"key":"1432_CR26","volume-title":"An International System for Human Cytogenetic Nomenclature (1995): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature","author":"F Mitelman","year":"1994","unstructured":"Mitelman F. An International System for Human Cytogenetic Nomenclature (1995): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Memphis, Tennessee, USA: Karger Medical and Scientific Publishers; 1994."},{"key":"1432_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3324\/haematol.2012.067892","volume":"98","author":"B Deschler","year":"2013","unstructured":"Deschler B, Ihorst G, Platzbecker U, Germing U, M\u00e4rz E, de Figuerido M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98:208\u201316.","journal-title":"Haematologica"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1432-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1432-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T13:24:55Z","timestamp":1630589095000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1432-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,26]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1432"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1432-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,26]]},"assertion":[{"value":"20 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"430"}}